Results 61 to 70 of about 1,701 (184)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVResearch in context

EBioMedicine, 2023
Summary: Background: Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigation for HIV-1 pre-exposure ...
Adrienne E. Swanstrom, Robert J. Gorelick, Jorden L. Welker, Fabian Schmidt, Bing Lu, Kelly Wang, William Rowe, Matthew W. Breed, Kristin E. Killoran, Joshua A. Kramer, Duncan Donohue, James D. Roser, Paul D. Bieniasz, Theodora Hatziioannou, Cathi Pyle, James A. Thomas, Charles M. Trubey, Jim Zheng, Wade Blair, Stephen R. Yant, Jeffrey D. Lifson, Gregory Q. Del Prete   +21 more
doaj   +1 more source

HIV-1 capsid stability enables inositol phosphate-independent infection of target cells and promotes integration into genes.

PLoS Pathogens, 2023
The mature HIV-1 capsid is stabilized by host and viral determinants. The capsid protein CA binds to the cellular metabolites inositol hexakisphosphate (IP6) and its precursor inositol (1, 3, 4, 5, 6) pentakisphosphate (IP5) to stabilize the mature ...
Gregory A Sowd, Jiong Shi, Ashley Fulmer, Christopher Aiken   +3 more
doaj   +1 more source

Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 11, November 2026.
This review summarizes current therapeutic and prophylactic strategies for global viral diseases, including vaccines, PrEP, direct‐acting antivirals, and emerging modalities such as CRISPR and siRNA. It highlights their clinical impact, ongoing challenges, and future priorities toward broader protection, improved delivery, and more effective antiviral ...
Sawar Khan, Ayesha Nisar, Xiaoxu Li, Hao Yu, Abdul Qadeer, Sardar Azhar Mehmood, Imane Lamraoui, Sijie Liu, Lipeng Zhu, Xu Deng, Bo Kong, Kejun Zhong, Zanxian Xia   +12 more
wiley   +1 more source

Real‐world use and effectiveness of fostemsavir in a US clinical setting: Insights from Trio Health HIV Research Network

HIV Medicine, Volume 27, Issue 11, Page 1814-1822, November 2026.
Abstract Objective To describe real‐world patterns of use, virologic and immunologic outcomes and treatment persistence among people with HIV (PWH) initiating fostemsavir (FTR) in a diverse US cohort. Design Retrospective cohort study of adults receiving FTR in clinical practice, stratified by baseline viral suppression status.
Richard Elion, Cassidy Henegar, Isobel McEwen, Andrew Frick, Moti Ramgopal, Steven Santiago, Karam Mounzer, Gregory Huhn, Charles Walworth, Leigh Ragone, Vani Vannappagari   +10 more
wiley   +1 more source

Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered

AIDS
Objective: To assess efficacy, safety and pharmacokinetics (PK) of oral lenacapavir (LEN) when used as oral bridging (OB) between delayed subcutaneous (SC) LEN injections. Design: Post-hoc ...
Ogbuagu, Onyema E., Avihingsanon, Anchalee, Segal-Maurer, Sorana, Wang, Hui, Jogiraju, Vamshi K., Singh, Renu, Rhee, Martin S., Dvory-Sobol, Hadas, Sklar, Peter A., Molina, Jean-Michel   +9 more
openaire   +2 more sources

Binding of lenacapavir to HIV-1 CA.

Lenacapavir interacting with two CA molecules is represented based on a crystal structure (PDB ID: 6VKV) [70]. Two neighboring monomers are shown, their NTD and CTD domains have blue and green as well as orange and pink colors, respectively.
Gyula Hoffka (20904100), József Tőzsér (665273), Mohamed Mahdi (665270), János András Mótyán (3804706), Botond Lakatos (12478740)   +4 more
core   +1 more source

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals

, 2022
Objectives We evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across HIV-1 clades.
Bouba, Yagai, Ceccherini-Silberstein, Francesca, Sosso, Samuel Martin, Santoro, Maria, Takou, Désiré Komego, Ngueko, Aurelie Minelle Kengni, Fokam, Joseph, Teto, Georges, Fabeni, Lavinia, Dambaya, Béatrice, Ndjolo, Alexis, Carioti, Luca, Nka, Alex Durand, Pabo, Willy, Semengue, Ezéchiel Ngoufack Jagni, Colizzi, Vittorio, Armenia, Daniele, Perno, Carlo-Federico   +17 more
core   +1 more source

Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre‐exposure prophylaxis: A focus on polypharmacy and transitions of care in the United States

British Journal of Clinical Pharmacology, EarlyView.
Shawnalyn W. Sunagawa, Elizabeth M. Sherman, Melissa Badowski, David B. Cluck, Spencer H. Durham, Joshua P. Havens, Emily Huesgen, Justin K. Ma, Roxane Rohani, Eric G. Sahloff, Kristy M. Shaeer, Radhika S. Polisetty   +11 more
wiley   +1 more source

Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV‐1 Reverse Transcriptase

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
HIV‐1 reverse transcriptase (HIV‐1 RT) is a polymerase enzyme and a key target in HIV‐1 therapy. The discovery of selective HIV‐1 RT inhibitors has highlighted thiazole scaffolds and their derivatives, thiazolidine‐2‐one and thiazolidine‐2,4‐dione, as promising structures for the rational design of novel non‐nucleoside reverse transcriptase inhibitors (
José Arion da Silva Moura, Matheus Vinicius Guimarães de Melo, Diane Regis Santos do Nascimento, Thaynara Paula Warren Bezerra, Mathieu Métifiot, Patricia Recordon‐Pinson, Maira Galdino da Rocha Pitta, Marina Galdino da Rocha Pitta, Michelly Cristiny Pereira, Marie‐Line Andreola   +9 more
wiley   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, Volume 13, Issue 59, 23 October 2026.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source